440 related articles for article (PubMed ID: 29036902)
1. DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer.
Stiborová M; Arlt VM; Schmeiser HH
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036902
[TBL] [Abstract][Full Text] [Related]
2. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
3. Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats.
Bárta F; Dedíková A; Bebová M; Dušková Š; Mráz J; Schmeiser HH; Arlt VM; Hodek P; Stiborová M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638820
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy.
Stiborová M; Frei E; Arlt VM; Schmeiser HH
Mutat Res; 2008; 658(1-2):55-67. PubMed ID: 17851120
[TBL] [Abstract][Full Text] [Related]
5. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.
Arlt VM; Stiborová M; vom Brocke J; Simões ML; Lord GM; Nortier JL; Hollstein M; Phillips DH; Schmeiser HH
Carcinogenesis; 2007 Nov; 28(11):2253-61. PubMed ID: 17434925
[TBL] [Abstract][Full Text] [Related]
6. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
Schmeiser HH; Nortier JL; Singh R; Gamboa da Costa G; Sennesael J; Cassuto-Viguier E; Ambrosetti D; Rorive S; Pozdzik A; Phillips DH; Stiborova M; Arlt VM
Int J Cancer; 2014 Jul; 135(2):502-7. PubMed ID: 24921086
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
8. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
9. The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats.
Stiborová M; Bárta F; Levová K; Hodek P; Frei E; Arlt VM; Schmeiser HH
Arch Toxicol; 2015 Nov; 89(11):2141-58. PubMed ID: 25209566
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
11. Chemical and molecular basis of the carcinogenicity of Aristolochia plants.
Schmeiser HH; Stiborovà M; Arlt VM
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):141-8. PubMed ID: 19152223
[TBL] [Abstract][Full Text] [Related]
12. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.
Schmeiser HH; Kucab JE; Arlt VM; Phillips DH; Hollstein M; Gluhovschi G; Gluhovschi C; Modilca M; Daminescu L; Petrica L; Velciov S
Environ Mol Mutagen; 2012 Oct; 53(8):636-41. PubMed ID: 22987305
[TBL] [Abstract][Full Text] [Related]
13. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
[TBL] [Abstract][Full Text] [Related]
14. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
15. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR.
Arlt VM; Schmeiser HH; Pfeifer GP
Carcinogenesis; 2001 Jan; 22(1):133-40. PubMed ID: 11159751
[TBL] [Abstract][Full Text] [Related]
16. Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy--an environmental form of the aristolochic acid nephropathy.
Karanović S; Lela IV; Jelaković B; Dickman KG; Peić AK; Dittrich D; Knežević M; Matijević V; Fernandes AS; Miller F
Kidney Blood Press Res; 2013; 37(1):1-8. PubMed ID: 23445829
[TBL] [Abstract][Full Text] [Related]
17. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
[TBL] [Abstract][Full Text] [Related]
18. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
19. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
20. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
